Literature DB >> 14748210

Treatment of Marburg variant multiple sclerosis with mitoxantrone.

Douglas R Jeffery1, David S Lefkowitz, Jeffrey P Crittenden.   

Abstract

Marburg variant multiple sclerosis (MS) is a severe, sometimes monophasic, form of MS leading to advanced disability or death within a period of weeks to months. No consistently successful treatment for Marburg variant MS has been described. The case reported here is that of a 34-year-old woman with Marburg variant MS whose magnetic resonance imaging scan showed extensive brainstem, periventricular white matter, subcortical, and cortical involvement, giving the appearance of an "MS cerebritis." The patient had no response to treatment with methylprednisolone but improved and recovered after treatment with mitoxantrone (MITX). Because MITX has potent anti-inflammatory effects and demonstrated efficacy in worsening MS, it may be an appropriate agent for the treatment of Marburg variant MS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14748210

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  14 in total

1.  Professor Otto Marburg, universal neurologist and the 'dean of teachers'.

Authors:  Lazaros C Triarhou
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 2.  Isolated, relapsing and progressive demyelinating diseases of the central nervous system.

Authors:  Axel Petzold
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

3.  Marburg's disease: a diagnostic dilemma.

Authors:  Kirti Gupta; Rakesh Kumar Vasishta; Param Singh Kharbanda; Sameer Vyas; Sudesh Prabhakar
Journal:  Neurol Sci       Date:  2011-08-06       Impact factor: 3.307

4.  Fulminant multiple sclerosis (MS).

Authors:  Mohammad Rohani; Shadi Ghourchian
Journal:  Neurol Sci       Date:  2011-08-24       Impact factor: 3.307

5.  14th EUNOS Congress: PORTO, PORTUGAL, 16-19 JUNE 2019.

Authors: 
Journal:  Neuroophthalmology       Date:  2019-06-07

6.  Long survival and clinical stability in Marburg's variant multiple sclerosis.

Authors:  Marco Turatti; Alberto Gajofatto; Francesca Rossi; Marcella Vedovello; Maria Donata Benedetti
Journal:  Neurol Sci       Date:  2010-05-12       Impact factor: 3.307

7.  Fulminant demyelinating diseases.

Authors:  Megan R Rahmlow; Orhun Kantarci
Journal:  Neurohospitalist       Date:  2013-04

8.  Language impairment and right hemiparesis in a 54-year-old woman.

Authors:  Alexander Venizelos; John Lee; José Biller
Journal:  Front Neurol       Date:  2011-07-01       Impact factor: 4.003

Review 9.  Idiopathic inflammatory-demyelinating diseases of the central nervous system.

Authors:  A Rovira Cañellas; A Rovira Gols; J Río Izquierdo; M Tintoré Subirana; X Montalban Gairin
Journal:  Neuroradiology       Date:  2007-02-28       Impact factor: 2.995

10.  Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue.

Authors:  Valeria Koska; Moritz Förster; Katja Brouzou; Maryam Hatami; Ercan Arat; Ahmet Aytulun; Philipp Albrecht; Orhan Aktas; Patrick Küry; Sven G Meuth; David Kremer
Journal:  Front Neurol       Date:  2021-06-23       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.